Jacob D. Bitran

4.5k total citations
138 papers, 3.0k citations indexed

About

Jacob D. Bitran is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Jacob D. Bitran has authored 138 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 50 papers in Pulmonary and Respiratory Medicine and 32 papers in Pathology and Forensic Medicine. Recurrent topics in Jacob D. Bitran's work include Lung Cancer Research Studies (27 papers), Lung Cancer Treatments and Mutations (26 papers) and Lymphoma Diagnosis and Treatment (24 papers). Jacob D. Bitran is often cited by papers focused on Lung Cancer Research Studies (27 papers), Lung Cancer Treatments and Mutations (26 papers) and Lymphoma Diagnosis and Treatment (24 papers). Jacob D. Bitran collaborates with scholars based in United States, Italy and Canada. Jacob D. Bitran's co-authors include Harvey M. Golomb, Carlos Bekerman, Brian L. Samuels, Richard K. Desser, Stephanie Williams, S F Williams, John E. Ultmann, Paul B. Hoffer, Rosemarie Mick and Philip C. Hoffman and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Jacob D. Bitran

129 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jacob D. Bitran United States 32 1.5k 1.1k 578 462 414 138 3.0k
Byron M. Espina United States 29 1.6k 1.1× 1.0k 1.0× 959 1.7× 455 1.0× 333 0.8× 73 3.5k
Johannes Blom Sweden 25 1.3k 0.8× 739 0.7× 435 0.8× 278 0.6× 330 0.8× 87 2.4k
Mustafa Beneklı Türkiye 24 1.2k 0.8× 601 0.6× 470 0.8× 623 1.3× 257 0.6× 182 2.6k
Thomas J. Ervin United States 27 1.3k 0.9× 845 0.8× 474 0.8× 760 1.6× 173 0.4× 81 2.9k
Antoine Thyss France 32 1.7k 1.1× 885 0.8× 695 1.2× 783 1.7× 259 0.6× 111 3.5k
Ian Quirt Canada 31 1.5k 1.0× 839 0.8× 316 0.5× 849 1.8× 261 0.6× 80 2.8k
Chul Won Choi South Korea 28 851 0.6× 657 0.6× 664 1.1× 487 1.1× 198 0.5× 192 2.8k
R. Lamerz Germany 29 1.9k 1.2× 761 0.7× 762 1.3× 1.4k 3.0× 365 0.9× 107 4.0k
M. Hayat France 33 1.4k 0.9× 916 0.9× 1.4k 2.3× 502 1.1× 280 0.7× 101 3.7k
R. S. Bush Canada 35 934 0.6× 898 0.8× 920 1.6× 341 0.7× 245 0.6× 75 3.4k

Countries citing papers authored by Jacob D. Bitran

Since Specialization
Citations

This map shows the geographic impact of Jacob D. Bitran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacob D. Bitran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacob D. Bitran more than expected).

Fields of papers citing papers by Jacob D. Bitran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacob D. Bitran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacob D. Bitran. The network helps show where Jacob D. Bitran may publish in the future.

Co-authorship network of co-authors of Jacob D. Bitran

This figure shows the co-authorship network connecting the top 25 collaborators of Jacob D. Bitran. A scholar is included among the top collaborators of Jacob D. Bitran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacob D. Bitran. Jacob D. Bitran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bitran, Jacob D., et al.. (2025). Advances in Therapy of Adult Patients with Acute Lymphoblastic Leukemia. Cells. 14(5). 371–371.
3.
4.
Bitran, Jacob D., et al.. (2023). A Case of Recurrent Multiple Myeloma as Testicular Plasmacytoma Without Systemic Disease. Cureus. 15(6). e40785–e40785. 1 indexed citations
5.
Kuruvilla, John, Philippe Armand, Mehdi Hamadani, et al.. (2022). Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. Leukemia & lymphoma. 64(1). 130–139. 12 indexed citations
6.
Chandran, Anjana, et al.. (2022). Mantle Zone Lymphoma With Prostate Gland Enlargement: A Case Report. Cureus. 14(11). e32045–e32045.
7.
Nabhan, Chadi, Nancy Davis, Jacob D. Bitran, et al.. (2010). Efficacy and safety of clofarabine in relapsed and/or refractory non‐hodgkin lymphoma, including rituximab‐refractory patients. Cancer. 117(7). 1490–1497. 13 indexed citations
8.
Radhakrishnan, Amruta, et al.. (2009). Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial. Journal of Chemotherapy. 21(4). 439–444. 6 indexed citations
9.
Ueno, Naoto T., J. Douglas Rizzo, Taner Demirer, et al.. (2007). Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplantation. 41(6). 537–545. 47 indexed citations
10.
Chiappori, Alberto, Peter Ellis, John Hamm, et al.. (2006). A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 1(9). 1010–1019. 12 indexed citations
11.
12.
Gale, Robert Peter, Rolla Edward Park, Robert W. Dubois, et al.. (2000). Delphi‐panel analysis of appropriateness of high‐dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clinical Transplantation. 14(1). 32–41. 13 indexed citations
13.
Bitran, Jacob D., et al.. (1996). Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy.. PubMed. 2(9). 1509–13. 43 indexed citations
14.
Bitran, Jacob D., Mark A. Green, Michael C. Perry, Donna Hollis, & James E. Herndon. (1995). A Phase II Study of Recombinant Interferon-Gamma Following Combination Chemotherapy for Patients with Extensive Small Cell Lung Cancer. American Journal of Clinical Oncology. 18(1). 67–70. 9 indexed citations
15.
16.
Williams, S F, et al.. (1989). High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer.. Journal of Clinical Oncology. 7(12). 1824–1830. 88 indexed citations
17.
Vokes, Everett E., Jacob D. Bitran, Philip C. Hoffman, et al.. (1989). Neoadjuvant Vindesine, Etoposide, and Cisplatin for Locally Advanced Non-Small Cell Lung Cancer. CHEST Journal. 96(1). 110–113. 37 indexed citations
18.
Bekerman, Carlos & Jacob D. Bitran. (1988). Gallium-67 scanning in the clinical evaluation of human immunodeficiency virus infection: Indications and limitations. Seminars in Nuclear Medicine. 18(4). 273–286. 11 indexed citations
19.
Bitran, Jacob D., Richard K. Desser, Thomas Demeester, & Harvey M. Golomb. (1978). Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP).. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 240(25). 2743–6. 29 indexed citations
20.
DeMeester, Tom R., Carlos Bekerman, Harvey M. Golomb, et al.. (1976). Gallium-67 scanning for carcinoma of the lung. Journal of Thoracic and Cardiovascular Surgery. 72(5). 699–708. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Byron M. Espina Breakdown of academic impact, for papers by Johannes Blom Breakdown of academic impact, for papers by Mustafa Beneklı Breakdown of academic impact, for papers by Thomas J. Ervin Breakdown of academic impact, for papers by Antoine Thyss Breakdown of academic impact, for papers by Ian Quirt Breakdown of academic impact, for papers by Chul Won Choi Breakdown of academic impact, for papers by R. Lamerz Breakdown of academic impact, for papers by M. Hayat Breakdown of academic impact, for papers by R. S. Bush
Rankless by CCL
2026